

Guidelines developed for perinatal hematologic cancers

December 7 2015



(HealthDay)—Consensus guidelines have been developed for clinical management of hematologic malignancies during the perinatal period, according to a special article published online Nov. 30 in the *Journal of Clinical Oncology*.

Noting that the incidence of <a href="https://www.nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.org/nemo.or



The team reviewed diagnostic and novel therapeutic approaches and integrated new information into treatment protocols. The guidelines relate to diagnostic procedures, chemotherapy use, radiotherapy use, and maternal supportive care. The authors also address perinatal and pediatric aspects of care.

"This consensus summary equips <u>health care professionals</u> with novel diagnostic and treatment methodologies that aim for optimal treatment of the mother, while protecting fetal and pediatric health," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Guidelines developed for perinatal hematologic cancers (2015, December 7) retrieved 4 May 2024 from https://medicalxpress.com/news/2015-12-guidelines-perinatal-hematologic-cancers.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.